Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates in two segments, EVT Execute and EVT Innovate. The EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody platform; INDiGO, a program for accelerating the early drug candidates into the clinic stage; integrated chemistry, manufacturing, and control services; and integrated drug discovery services. The EVT Innovate segment is involved in investing and developing proprietary assets, including early-stage discovery programs, as well as advanced drug candidates in the areas of diabetes and diabetic complications, inflammatory diseases, neuroscience, oncology, and pain and anti-infective. Evotec SE has a strategic drug discovery and development partnership with Celgene Corporation; strategic research alliance with Novo Nordisk A/S; collaboration with Sanofi; research collaboration with Almirall; research alliance with Ferring Pharmaceuticals; strategic collaboration with Centogene; collaboration with Immuneering; and drug discovery alliance with LEO Pharma. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-40-560810
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$375.40 million
Profitability
Miscellaneous
Employees2,617
Next Earnings DateN/A
OptionableNot Optionable
Evotec (ETR:EVT) Frequently Asked Questions
What is Evotec's stock symbol?
Evotec trades on the ETR under the ticker symbol "EVT."
What price target have analysts set for EVT?
3 brokerages have issued 1-year target prices for Evotec's stock. Their forecasts range from €20.00 to €26.00. On average, they anticipate Evotec's stock price to reach €23.00 in the next twelve months. This suggests that the stock has a possible downside of 4.2%. View Analyst Price Targets for Evotec.
What is the consensus analysts' recommendation for Evotec?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Evotec.
Has Evotec been receiving favorable news coverage?
News coverage about EVT stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evotec earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
Who are some of Evotec's key competitors?
Some companies that are related to Evotec include Aurora Cannabis (ACB), Bausch Health Companies (BHC), Hikma Pharmaceuticals (HIK), Aphria (APHA), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Green Organic Dutchman (TGOD), CannTrust (TRST), Knight Therapeutics (GUD), Supreme Cannabis (FIRE), Flowr (FLWR), Supreme Cannabis (FIRE), HLS Therapeutics (HLS) and HLS Therapeutics (HLS).
What other stocks do shareholders of Evotec own?
Who are Evotec's key executives?
Evotec's management team includes the folowing people:
- Dr. Werner Lanthaler, CEO & Member of Management Board (Age 51)
- Mr. Enno Spillner, CFO & Member of Management Board (Age 49)
- Dr. Cord Dohrmann, Chief Scientific Officer & Member of Management Board (Age 55)
- Dr. Craig Johnstone, COO & Member of Management Board
- Ms. Anja Bosler, Principal Accounting Officer and Sr. VP of Group Accounting
What is Evotec's stock price today?
One share of EVT stock can currently be purchased for approximately €24.00.
How big of a company is Evotec?
Evotec has a market capitalization of $3.57 billion and generates $375.40 million in revenue each year. Evotec employs 2,617 workers across the globe.
What is Evotec's official website?
How can I contact Evotec?
Evotec's mailing address is Essener Bogen 7, HAMBURG, 22419, Germany. The company can be reached via phone at +49-40-560810.
MarketBeat Community Rating for Evotec (ETR EVT)
MarketBeat's community ratings are surveys of what our community members think about Evotec and other stocks. Vote "Outperform" if you believe EVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
